This review demonstrates the complex links between oxidative stress and neuroinflammation in Alzheimer's disease, suggesting multi-targeted therapies could improve outcomes.
Key Points
AGE-RAGE signaling plays a critical role in the pathogenesis of Alzheimer's disease, amplifying oxidative stress and metabolic dysfunction.
Recent literature indicates a connection between Alzheimer's disease and type 2 diabetes, with metabolic dysregulation contributing to disease progression.
Natural and pharmacological agents like antioxidants and antiglycation compounds have shown potential in mitigating AGE-related damage in Alzheimer's disease.
The review advocates for personalized therapeutic strategies targeting multiple axes, including AGE-RAGE inhibition and metabolic regulation, for more effective treatment.